These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9797804)

  • 21. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
    Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
    Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
    Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
    Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
    Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
    Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemosensitivity and chemoresistance testing in ovarian cancer.
    Cree IA
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
    Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of lung resistant-related protein in ovarian cancer and its clinical significance].
    Qian XL; Peng ZL; Liu SL; Wang H; Ni J
    Ai Zheng; 2002 Dec; 21(12):1332-4. PubMed ID: 12520742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS; Taylor DD; Gercel-Taylor C
    Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.
    Prasad M; Bernardini M; Tsalenko A; Marrano P; Paderova J; Lee CH; Ben-Dor A; Barrett MT; Squire JA
    Genes Chromosomes Cancer; 2008 May; 47(5):427-36. PubMed ID: 18273836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
    Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
    Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
    Song J; Shih IeM; Salani R; Chan DW; Zhang Z
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
    Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
    Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
    Asada N; Tsuchiya H; Tomita K
    Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
    Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.